OraSure Technologies (NASDAQ:OSUR) Price Target Lowered to $3.00 at Stephens

OraSure Technologies (NASDAQ:OSUR) had its price target cut by Stephens from $3.50 to $3.00 in a report published on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the medical instruments supplier’s stock.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of OraSure Technologies in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Stock Performance

OraSure Technologies stock traded down $0.19 during midday trading on Wednesday, reaching $2.28. 729,398 shares of the company were exchanged, compared to its average volume of 700,813. The firm’s 50-day simple moving average is $3.02 and its 200-day simple moving average is $2.98. OraSure Technologies has a 1 year low of $2.27 and a 1 year high of $4.22. The company has a market capitalization of $163.55 million, a price-to-earnings ratio of -3.40 and a beta of 0.54.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 5th. The medical instruments supplier reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $27.09 million during the quarter, compared to the consensus estimate of $28.96 million. OraSure Technologies had a negative net margin of 36.84% and a negative return on equity of 10.81%. OraSure Technologies has set its Q4 2025 guidance at EPS. On average, analysts forecast that OraSure Technologies will post -0.08 EPS for the current fiscal year.

Hedge Funds Weigh In On OraSure Technologies

A number of hedge funds have recently bought and sold shares of OSUR. Private Management Group Inc. bought a new position in OraSure Technologies during the 1st quarter worth approximately $14,886,000. Gagnon Securities LLC bought a new position in OraSure Technologies during the first quarter worth $3,619,000. Gagnon Advisors LLC acquired a new position in OraSure Technologies in the first quarter worth $2,687,000. Systematic Financial Management LP raised its holdings in shares of OraSure Technologies by 35.3% during the second quarter. Systematic Financial Management LP now owns 2,229,076 shares of the medical instruments supplier’s stock worth $6,687,000 after purchasing an additional 581,926 shares during the period. Finally, Cannell Capital LLC raised its position in shares of OraSure Technologies by 33.7% during the 2nd quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock worth $5,595,000 after purchasing an additional 470,536 shares during the period. 93.50% of the stock is currently owned by institutional investors and hedge funds.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.